<DOC>
	<DOCNO>NCT01750112</DOCNO>
	<brief_summary>This prospective , open , non-comparative baseline-controlled study evaluate efficacy safety Macrolane VRF20 treatment 40 subject pectus excavatum deformity . Each subject participate study treat approximately 50-150 ml Macrolane VRF20 . The amount study product use individually determined order achieve optimal correction deformity subject .</brief_summary>
	<brief_title>Treatment Pectus Excavatum Deformity Using Macrolane Filler</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Funnel Chest</mesh_term>
	<criteria>1 . Give verbal write informed consent participate study . 2 . Be healthy male 18 year . 3 . Have pectus excavatum deformity without functional problem ; score 4 item 10 , 11 12 PEEQ , indicate functional impairment due pectus excavatum deformation . 4 . Present normal cardiac function assess ECG echocardiogram . 5 . Present normal pulmonary function assess pulmonary function test . 6 . Present chest Xray take within 12 month prior baseline visit , without clinically significant defect heart , lung , skeleton , rib , sternum spinal cord except pectus excavatum defect , opinion Investigator . 7 . Have ability understand comply requirement study . 1 . Score 1 , 2 3 either item 10 , 11 12 PEEQ , indicative functional problem due pectus excavatum deformity . 2 . Previous treatment indication . 3 . Known suspected hypersensitivity hyaluronic acid base product . 4 . BMI &lt; 20 . 5 . A history severe allergy manifest history anaphylaxis , history presence multiple severe allergy ( judged Investigator ) . 6 . Known allergy anesthesia plan study . 7 . Presence autoimmune disease chronic disease opinion Investigator may interfere outcome study . 8 . Subjects bleed disorder subject take thrombolytic anticoagulant , take inhibitor platelet aggregation , include nonsteroidal antiinflammatory agent acetylsalicylic acid , two week treatment . 9 . Subjects immunomodulatory therapy ( suppressive stimulatory ) . 10 . Subjects contraindication MRI , presence pacemaker , clip splinter , tendency claustrophobia . 11 . Any condition opinion Investigator make subject unsuitable inclusion ( e.g. , subject likely participate duration study ) . 12 . Use investigational drug device within 30 day prior baseline . 13 . Subjects study site staff study , close relative study site staff , well subject employ Sponsor company , close relative employee Sponsor company .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pectus excavatum</keyword>
	<keyword>funnel chest</keyword>
	<keyword>sink chest</keyword>
</DOC>